Abeona Therapeutics Stock Alpha and Beta Analysis
| ABEO Stock | USD 6.03 0.09 1.52% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Abeona Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Abeona Therapeutics over a specified time horizon. Remember, high Abeona Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Abeona Therapeutics' market risk premium analysis include:
Beta 0.68 | Alpha 0.0522 | Risk 2.54 | Sharpe Ratio 0.0632 | Expected Return 0.16 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Abeona |
Abeona Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Abeona Therapeutics market risk premium is the additional return an investor will receive from holding Abeona Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Abeona Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Abeona Therapeutics' performance over market.| α | 0.05 | β | 0.68 |
Abeona Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Abeona Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Abeona Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Abeona Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Abeona Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Abeona Therapeutics shares will generate the highest return on investment. By understating and applying Abeona Therapeutics stock market price indicators, traders can identify Abeona Therapeutics position entry and exit signals to maximize returns.
Abeona Therapeutics Return and Market Media
The median price of Abeona Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 6.04 with a coefficient of variation of 6.52. The daily time series for the period is distributed with a sample standard deviation of 0.39, arithmetic mean of 6.06, and mean deviation of 0.35. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Abeona Therapeutics Announces Participation in Upcoming Investor Conferences | 09/03/2024 |
2 | Disposition of 496 shares by Omalley Brendan M. of Abeona Therapeutics at 6.02 subject to Rule 16b-3 | 09/20/2024 |
3 | Cantor Fitzgerald Reaffirms Overweight Rating for Abeona Therapeutics | 09/23/2024 |
4 | Disposition of 6388 shares by Joseph Vazzano of Abeona Therapeutics at 5.89 subject to Rule 16b-3 | 09/27/2024 |
5 | Abeona Therapeutics Inc Sees Significant Decline in Short Interest | 10/01/2024 |
6 | Disposition of 251 shares by Seshadri Vishwas of Abeona Therapeutics at 6.54 subject to Rule 16b-3 | 10/16/2024 |
7 | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | 11/01/2024 |
8 | Rosalind Advisors, Inc. Increases Stake in Delcath Systems Inc | 11/15/2024 |
9 | Abeona Therapeutics Upgraded by StockNews.com to Hold Rating - MarketBeat | 11/20/2024 |
10 | Abeona shares retain Buy rating H.C. Wainwright sees approval potential for pz-cel in RDEB | 11/25/2024 |
About Abeona Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Abeona or other stocks. Alpha measures the amount that position in Abeona Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 1.6K | 1.6K | Price To Sales Ratio | 30.6 | 29.07 |
Abeona Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Abeona Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Abeona Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Abeona Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Abeona Therapeutics. Please utilize our Beneish M Score to check the likelihood of Abeona Therapeutics' management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Abeona Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Abeona Therapeutics Backtesting, Abeona Therapeutics Valuation, Abeona Therapeutics Correlation, Abeona Therapeutics Hype Analysis, Abeona Therapeutics Volatility, Abeona Therapeutics History and analyze Abeona Therapeutics Performance. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Abeona Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.